Applying transcriptional profiling analysis to myeloblasts from 59 adult patients with acute 22 myeloid leukemia (AML) treated at our institution, we found that expression of the three-amino 23 acid loop extension (TALE) homeobox gene TG-Interacting Factor 1 (TGIF1) correlated with 24 overall and relapse-free survival, which was then confirmed in two other cohorts of patients. 25
Introduction 34
Acute myeloid leukemia (AML) is an aggressive and heterogeneous disease that most commonly 35 occurs in the elderly. Although a majority of patients achieve a complete remission (CR) with 36 induction and consolidation chemotherapy, most will eventually relapse, with overall survival 37 (OS) ranging from 10-35% 1, 2 . As a result, clinical indicators have been sought that could inform 38 post-remission therapy and improve long-term survival 3, 4 . Established predictors of outcome 39 include patient age, white blood cell (WBC) count, antecedent myelodysplastic syndrome, and, 40 of greatest significance, the presence of specific chromosomal rearrangements in leukemia cells 41 5 . Patients with t(15;17), t(8;21), or inv(16) enjoy the longest overall survival (OS), while t(6;9), 42 11q23, monosomy of chromosomes 5 or 7, and complex karyotypes confer the worst prognoses, 43 with 80% of these individuals ultimately relapsing 6 . The largest group of patients, however, has 44 either a normal karyotype or specific cytogenetic abnormalities that put them at some 45 intermediate risk of relapse and death 7, 8 . 46
Patients in the favorable risk group can be successfully treated with intensive chemotherapy 47 only 8 , while those in the high-risk group require an allogeneic hematopoietic stem cell transplant 48 (SCT) in remission for long term survival 9 . In contrast, the optimum therapy for intermediate-49
risk patients is unclear. Given the substantial number of individuals in whom a cytogenetic 50 marker is not present or prognostic, additional, especially molecular, predictors of survival have 51 been sought. One of the most extensively characterized molecular abnormalities is an internal 52 tandem duplication (ITD) of the gene for Fms-Related Tyrosine Kinase 3 (FLT3). While found 53 to impact survival in some analyses 10, 11 , no difference in that of FLT3 ITD-positive and ITD-54 negative patients was detected in other studies 12, 13 as assessed independently of other mutations, 55 in particular those in the nucleophosmin (NPM1) gene. More than one ITD 10 , a high ratio of 56 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.04.20020537 doi: medRxiv preprint TGIF1 expression is associated with clinical outcomes in AML. To identify new predictors of 79 outcome, we carried out microarray analysis of leukemia cellular RNA from 59 of the 60 adult 80 patients with AML treated at our institution ( Supplemental Table S1 ). Modified Cox regression 81 analysis was then used to identify genes whose expression correlated with OS. A group of 38 82 genes were predictive with a P < 0.001 and of 5 genes with a P < 0.0001, while the expression of 83 a single gene, TGIF1, correlated with OS with the greatest significance (P < 0.00001). 84
Kaplan-Meier analysis of patient survival in this cohort showed that only 8% (3/39) of 85 individuals whose leukemia cells contained lower levels of TGIF1 mRNA than the reference 86 remained alive at last follow-up (median survival = 181 days, confidence interval (CI) = 112-249 87 days), while 60% (12/20) of patients who expressed TGIF1 at higher levels survived. Since more 88 than half of patients with higher TGIF1 expression were living at last analysis, median survival 89 could not be determined. Log-rank analysis revealed that individuals with lower TGIF1 90 expression had significantly shorter OS ( Figure 1A ) and relapse-free survival (RFS) ( Figure 1B ) 91 than the group with higher expression. Although a commercial RNA preparation was used to 92 stratify patients into lower and higher expressers, the best cut-point in TGIF1 expression for 93 discriminating survival determined by receiver operating characteristic analysis was close to that 94 in the commercial reference (data not shown). When patients were segregated by TGIF1 95 expression in quartiles, a concentration-dependent relationship between TGIF1 expression and 96 outcome was suggested (Figure 2A ). Finally, TGIF1 expression correlated with OS with even 97 greater statistical significance when analyzed as a continuous variable (P < 0.0001). 98
TGIF1 expression correlated with survival for risk groups defined by cytogenetics analysis. 100
Seventeen percent (1/6) and 86% (18/21) of patients with good-and poor-risk cytogenetic 101 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.04.20020537 doi: medRxiv preprint findings, respectively, had lower TGIF1 expression. In contrast, TGIF1 expression was more 102 evenly distributed in patients with a normal karyotype. Specifically, 41% (11/27) had higher and 103 59% (16/27) lower TGIF1 mRNA than reference, and individuals in the intermediate-risk group 104 with lower TGIF1 survived for significantly shorter times (median survival = 201 days, CI = 105 138-263 days) than those with higher expression (median survival = 1566 days). TGIF1 106 expression also correlated with shorter OS for patients in poor-risk patients (data not shown) and 107 even for the good-risk group, although the number of patients was small. Thus, TGIF1 levels 108 correlated with clinical outcome in adult AML patients from all three cytogenetic risk groups. 109
110

TGIF1 expression correlated with survival in independent cohorts of AML patients. To 111
substantiate the association between TGIF1 expression and survival observed in the discovery 112 group, we reanalyzed hybridization data from a published study 23 and related leukemia cell 113 TGIF1 expression to survival in this larger (n = 285) group of patients. When patients were 114 segregated into 5 groups according to myeloblast TGIF1 RNA abundance and trend and log-rank 115 analysis of survival in these patients was carried out, a concentration-or dose-dependence in 116 survival was observed ( Figure 2B ). We also investigated whether TGIF1 expression differed in 117 five patient clusters, 5, 9, 10, 12, and 13 23 . Cluster 5 consisted of FAB class M4 or M5 118 leukemias, cluster 10 expressed the EVI1 oncogene, and clusters 9, 12 and 13 were defined by 119 the presence of (inv)16, t(15;17), and t(8;21), respectively. Consistent with the association of 120 t(15;17), t(8;21), and inv(16) with a better outcome and the inverse association between EVI1 121 expression and survival 14 , OS was shorter in patients in clusters 5 and 10 compared to 9, 12, and 122 13 23 ( Figure 2B ). Mean TGIF1 levels differed significantly between these clusters (P < 0.0001), 123
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The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.04.20020537 doi: medRxiv preprint with significant inter-group differences noted between clusters 5 and 9 (P = 0.0001), 5 and 12 (P 124 < 0.0001), 5 and 13 (P < 0.0001), 10 and 12 (P < 0.0001), and 10 and 13 (P = 0.0003). 125
Finally, OS was significantly worse in AML patients from The Cancer Genome Atlas 126 (TCGA) whose TGIF1 expression was below the median than those with expression above the 127 median for both probe set 1566901_at (P < 0.0001) and 203313_s_at (P = 0.000254) 128 (http://servers.binf.ku.dk/bloodspot/?gene=TGIF1&dataset=normal_human_v2_with_AMLs) 129 (Supplemental Figure S1 ). This association was specific for TGIF1, as there was no difference in 130 survival according to expression of the related TGIF2 gene. Thus, analysis of multiple, 131 independent groups of patients confirmed the correlation between TGIF1 gene expression and 132 outcome and, for the European cohort, the quantitative nature of this relationship. 133
134
TGIF1 expression was unrelated to the presence of FLT3 gene mutations. To determine 135
whether decreased TGIF1 expression was related to FLT3 mutation, a widely used prognostic 136 factor in adults with AML, RNA from patient cells and the MV4-11 cell line, used as a positive 137 control for the FLT3 ITD 24 , were characterized by RT-PCR analysis. Of the 55 patients from 138 whom material was available for analysis, a FLT3 ITD was detected in 15 (27%) and the D835Y 139 missense mutation in two (4%). In two patients with a FLT3 ITD, no wild-type FLT3 RNA could 140 be detected at the sensitivity of this method, and in accord with published data 25 , these 141 individuals had very short survivals. In contrast, the OS of patients expressing mutant and wild-142 type FLT3 mRNA did not differ significantly from patients expressing only wild-type message in 143 our analysis (not shown). Importantly, no association between level of TGIF1 expression and 144 FLT3 mutation could be discerned (data not shown). These data thus argue against a model in 145 which mutational activation of FLT3 signaling represses TGIF1 expression. 146 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
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Reduced TGIF1 expression in myeloid leukemia cells was not associated with sequence 148
variants. The association between decreased TGIF1 expression and shorter survival could be 149 compatible with a tumor suppressor function for this transcription factor. Since well-150 characterized loss-of-function mutations in this gene have been described in a human genetic 151 disorder, we undertook analysis of TGIF1 coding and 5´ untranslated sequence for these or other 152 mutations in 49 patients in the discovery group. Although non-synonymous as well as 153 synonymous sequence variants were detected in 18 patients (37%), with previously unreported 154 single nucleotide polymorphisms found in five (Supplemental Table S2 ), none of these 155 corresponded to the mutations observed in patients with holoprosencephaly. Likewise, Southern 156 blot analysis did not reveal TGIF1 gene rearrangements in any patient studied (data not shown). 157
Thus, no definite abnormality in either gene sequence or structure was detected in any individual 158 with AML. 159
When TGIF1 mRNA abundance in myeloblasts was examined in aggregate, expression 160 appeared to vary in continuous fashion (Supplemental Figure S2 ). TGIF1 expression in 100 161 lymphoblastoid cell lines derived from normal individuals likewise appeared to be a continuous 162 variable, with an approximately 200-fold difference between the lowest and highest expresser 163 (Supplemental Figure S3 ). 164 165
Tgif1 gene loss decreased survival in an experimental model of acute myeloid leukemia. Given 166
our finding that TGIF1 expression correlated significantly with survival in AML, we sought to 167 determine if myeloblast TGIF1 abundance affected any aspect of leukemia cell biology. Our 168 previous study has shown that Tgif1 inactivity promotes the quiescence and the self-renewal 169 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
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Tgif1 knockout model 26 . To understand the role of Tgif1 in leukemia cells, in the present study, 
Tgif1 gene loss increased leukemia initiating cell frequency in MLL-AF9-induced AML. LICs 190
are thought to be crucial for the maintenance of AML in vivo [27] [28] [29] . Therefore, one explanation for 191 the shorter survival seen with Tgif1 loss could be higher numbers of leukemia initiating cells. To 192 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.04.20020537 doi: medRxiv preprint investigate, we carried out limiting dilution analysis of LIC number, transplanting serial numbers 193 of MLL-AF9-transduced Tgif1 +/+ or Tgif1 -/spleen cells from primary recipients into non-194 conditioned C57BL/6J mice. Indeed, there was a two-fold higher frequency of LICs in Tgif1 -/-195 mice with AML (1 in 125) (95% CI: lower; 1 in 279 and higher; 1 in 56.5) than in Tgif1 +/+ mice 196
(1 in 250) (95% CI: lower; 1 in 603 and higher; 1 in 103.6). These data suggest that Tgif1 - preparations from Tgif1 -/mice contained higher frequencies of LICs, we predicted that disease 203 induced by these cells would relapse earlier and progress more rapidly after treatment than 204 disease in mice receiving Tgif1 +/+ leukemia cells. To simulate the clinical setting, we 205
transplanted Tgif1 +/+ and Tgif1 -/-MLL-AF9-transformed-spleen cells from mice with established 206 leukemia into sub-lethally irradiated recipients and treated these mice with cytarabine and 207 doxorubicin chemotherapy as described 30 . For mice transplanted with Tgif1 -/leukemia cells, 208 GFP-expressing cells appeared earlier and in higher numbers in peripheral blood than in mice 209 transplanted with Tgif1 +/+ leukemia cells ( Figure 6A ). While treatment extended survival of both 210 Tgif1 +/+ and Tgif1 -/mice with AML (compare Figure 6B to Figure 5D ), mice transplanted with 211 Tgif1 -/leukemia cells still had shorter survival than mice transplanted with Tgif1 +/+ leukemia 212 cells ( Figure 6B ). Although selection at the level of a stem cell is not proven by these data, the 213 differences in latency of disease and response to chemotherapy, we posit, are due to the higher 214 frequency and/or greater fitness of LICs and more rapid expansion of leukemia in Tgif1 -/mice 215 (see Figure 6A ). 216 217
Tgif1 loss decreased survival in a model of chronic myeloid leukemia. Given data suggesting 218
Tgif1 expression impacted survival in AML, we went on to investigate whether Tgif1 loss also 219 affected leukemia cell biology in a mouse model of CML, a disease for which there is arguably 220 the greatest evidence for a malignant stem cell. To that end, lineage marker-negative (Lin -) 221
BMCs from Tgif1 +/+ and Tgif1 -/mice were transduced with the BCR-ABL-GFP retrovirus, 222 which were transplanted into sub-lethally or lethally irradiated recipient mice. After transplant, When recipient mice were conditioned with a lower dose of irradiation, leukemia developed with 230 a longer latency; however, Tgif1 genotype still significantly impacted survival ( Figure 7B ). 231
Interestingly, mice transplanted with BCR-ABL-transduced haploinsufficient (Tgif1 +/-) BMCs 232 also had shorter survivals (Supplemental Figure S5) , consistent with the greater long-term 233 repopulating ability of Tgif1 +/-HSCs compared to Tgif1 +/+ HSCs after transplantation 26 . In sum, 234 these data are compatible with the patient and mouse AML data and suggest Tgif1 expression 235 could also impact survival in CML. 236 237 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Tgif1 gene loss affected multiple transcriptional networks in AML. To gain insight into the 238
biological and molecular pathways affected by Tgif1 gene loss, we compared global gene 239 expression profiles in Tgif1 -/and Tgif1 +/+ myeloid leukemia cells using RNA-seq analysis. We 240 identified at least 45 genes that were differentially expressed in these two populations -33 of 241 these were significantly upregulated and 12 were down-regulated in Tgif1 -/relative to Tgif1 +/+ 242 leukemia cells (Table 1) . author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.04.20020537 doi: medRxiv preprint Our studies revealed that expression of the transcriptional regulator TGIF1 correlates 261 quantitatively with survival in adults with AML treated with standard induction and 262 consolidation chemotherapy, a finding that was validated in two other, independent cohorts of 263 patients. TGIF1 expression impacted outcome in each cytogenetic risk group, and, at least for 264 patients treated at our institution, was an independent risk factor in multivariate analysis. 265
Consistent with these results, we found that loss or haploinsufficiency of this gene accelerated 266 In light of studies demonstrating that LSC frequency at diagnosis in AML correlates with 281 increased minimal residual disease and poor survival 37 , the finding that reduced or absent 282 expression of Tgif1 in mouse models of myeloid leukemia enhanced LSC function provides at 283 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.04.20020537 doi: medRxiv preprint least one explanation for how it affects recurrence. Since effective therapy after relapse is 284 lacking in AML, except for hematopoietic stem cell transplantation in the case when a second 285 remission can be induced, this explains how patient survival would be impacted. 286
We found using a mouse model of AML that loss of Tgif1 resulted in a shorter latency in 287 development of leukemia, earlier relapse after chemotherapy, and inferior survival. In addition, 288
we found in a model of CML that heterozygous as well as homozygous loss of Tgif1 shortened 289 survival. These results underscore the quantitative relationship between TGIF1 abundance and 290 survival in AML patients and stem cell frequency in mice. They are also compatible with a 291 recent report demonstrating that enforced expression of TGIF1 decreased leukemia cell 292 proliferation, induced terminal differentiation, and increased survival in MLL-AF9 leukemia 38 . 293
Altogether, these data establish a biological basis for the association between TGIF1 expression 294 and clinical outcome. 295
In accord with its function as transcriptional repressor or corepressor, RNA expression 296 profiling identified a number of genes that were upregulated in Tgif1-null leukemia cells, with 297 almost half the genes differentially expressed in knockout and wild-type leukemia cells involved 298 directly or indirectly in TGF-β signaling (Supplemental Figure 6 ). This result also corroborates 299 the enhanced TGF-β signaling and/or target gene expression noted in epithelial 32 and myeloid 300 leukemia cells 39 in which TGIF1 expression was reduced by RNA interference. Importantly, 301 expression of the prototypic TGF-β target gene, plasminogen activator inhibitor-1, in human 302 myeloid leukemia cells correlated significantly with expression of a type I TGF-β receptor, 303 activin receptor-like kinase-5 (ALK-5), and presumably downstream signaling strength. Likely 304 for the reason offered here, ALK-5 expression, in turn, correlated inversely with achievement of 305 CR and with EFS, RFS, and OS 40 . 306 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.04.20020537 doi: medRxiv preprint Relevant to this work, TGF-β was shown to promote self-renewal in human HSCs 41 and 307 quiescence in murine HSCs 42 and to enhance the function of leukemia stem cells 41, 43-55 , which 308 could also explain the curative potential of a small-molecule inhibitor of the type I TGF-β 309 receptor 56, 57 added to a BCR-ABL tyrosine kinase inhibitor in CML in mice 51 . Together with 310 the gene expression results, these studies predict, therefore, that a TGF-β signaling inhibitor, 311 most logically used in combination with post-remission chemotherapy, would have the greatest 312 impact in patients with the lowest TGIF1 expression. 313
In addition to an effect on TGF-β target gene expression, loss of TGIF1 caused apparent 314 derepression of retinoic acid receptor (RAR) target genes, consistent with its ability to act as a 315 corepressor of RAR/RXR-mediated transcription. Finally, our results do not exclude direct 316 effects of TGIF1 on gene expression or indirect effects through interaction with other TALE 317 homeodomain proteins, MEIS1 for example 38 . As chemical inhibitors are available for TGF-β or 318 RAR signaling, it should be possible to determine which of these signaling pathways is most 319 important for TGIF1's actions in leukemia cells. It will also be important to determine whether 320 inhibition of these pathways, and TGF-β in particular, would have equivalent biological effects 321 on leukemic compared to normal stem cells, which would have therapeutic implications. 322
Although loss-of-function mutations in TGIF1 have been recognized in holoprosencehaly 35, 323 36 , we did not observe any coding or promoter mutations or any structural rearrangements of the 324 gene in AML patients. Furthermore, individuals with holoprosencephaly and Tgif1-null mice are 325 not at increased risk for development of myeloid leukemia, all of which argues against a function 326 of this protein as a tumor suppressor. Its graded expression in hematopoietic cells and dose-327 dependent effect on cell function, most clearly demonstrated for normal HSCs 26 , suggest that 328 TGIF1 acts as a quantitative trait locus in normal and malignant stem cell biology. In addition, 329 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
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In summary, by relating transcriptional profiles in myeloblasts from patients with AML to 332 survival, we have identified a new prognostic marker relevant, potentially, to all myeloid 333 leukemias. In addition, TGIF1 may be the prototype of a stem cell modifier gene, operating not 334 in the initiation of leukemia but in disease progression and persistence. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.04.20020537 doi: medRxiv preprint infusion from days 1-7 and 12 mg/m 2 of idarubicin or 45 mg/m 2 daunorubicin intravenously on 375 Amplification parameters consisted of an initial denaturation at 95°C for 3 min. This was 386 followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 56.7°C for 30 387 seconds, and extension at 75°C for 10 seconds. TGIF expression in leukemia samples was 388 quantified with the same reference RNA employed for the microarray studies, and relative 389 quantification of glyceraldehyde phosphate dehydrogenase (GAPDH) gene expression was 390 performed identically. Threshold cycles (CT) were determined for GAPDH and TGIF, and if the 391 GAPDH CT differed by three cycles or more between blast cell and reference cDNA, the 392 concentration and quality of RNA in that patient's sample was reevaluated. Four of the five 393 samples to which this applied were subsequently used after repeat determination of RNA 394 concentration. Primers were designed using the MacVector software package (Accelrys, San 395
Diego, CA). The sequences of the primers used in this analysis were: forward TGIF primer 396 CAGATTCTTCGGGATTGGCTG, reverse TGIF primer 397 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.04.20020537 doi: medRxiv preprint GGCGTTGATGAACCAGTTACAGAC, forward GAPDH primer 398 AATCCCCAGTGCTCCTTTTC, reverse GAPDH primer CAAAGTTGTCATCGATGACC. 399 400 TGIF mutational analysis. cDNA synthesis was carried out with the Superscript First-Strand 401 System (Invitrogen Life Technologies, Carlsbad, CA) using 1 µg of total cellular RNA and an 402 oligo(dT) primer. One-tenth volume of the first-strand reaction was then used as template for 403 PCR amplification (Elongase Amplification System, Invitrogen). The sequences of the primers 404 used in this analysis, corresponding to nucleotides 25-45 and 1489-1509, respectively, of TGIF 405 RNA sequence, were: forward primer GCAGGAGCAGGGAACAAAG, reverse primer 406 CAGTATGTGGGCATCCTGTTC. Amplification parameters consisted of an initial denaturation 407 at 94°C for 3 min, annealing at 56°C for 30 seconds, and extension at 72°C for 1 minute. This 408 was followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 56°C for 30 409 seconds, and extension at 68°C for 90 seconds and, terminally, extension at 68°C for 5 minutes. RNA. Total cellular RNA was purified using the RNeasy purification system (Qiagen) from 420 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
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The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.04.20020537 doi: medRxiv preprint Mice and plasmids. Mice with a Tgif1 null mutation have been previously described 26 . 444 C57BL/6J mice were purchased from the Jackson Laboratories (Bar Harbor, ME). All animal Transduced Tgif1 +/+ or Tgif1 -/-Lincells were resuspended in phosphate-buffered saline (PBS) 460 and 1 ´ 10 5 cells were injected intravenously into sub-lethally irradiated (4.5 Gy) Tgif1 +/+ or 461 Tgif1 -/recipient mice, respectively. Reconstitution of transduced cells in recipient mice was 462 evaluated by monitoring GFP expression in flow cytometry (FACS) analysis at 1-2 week 463 intervals following transplantation. Recipient mice were euthanized for analysis when they 464 developed palpable splenomegaly or appeared ill. Bone marrow and spleen cells from leukemic 465 mice were isolated and stored frozen for later use. 466
The MSCV-BCR/ABL-IRES-GFP retrovirus was used to induce CML in mice. Bone marrow 467 cells were flushed from the tibias and femurs of Tgif1 +/+ , Tgif1 +/-, or Tgif1 -/mice and single-cell 468 suspensions of Linc-Kit + cells were obtained using the Mouse Lineage Cell Depletion kit and 469 CD117 microbeads (Miltenyi Biotec, San Diego, CA). Linc-Kit + cells were spinoculated with 470 MSCV-BCR/ABL-IRES-GFP retrovirus in the presence of 8 μg/ml polybrene for 45 minutes at 471 1350g (32°C). Transduced cells were resuspended in PBS and 8 ´ 10 4 cells were injected 472 intravenously into lethally or sub-lethally irradiated C57BL/6J recipient mice. Reconstitution of 473 transduced cells in recipient mice was evaluated by FACS analysis of GFP expression two weeks 474 after transplantation. Mice were monitored for development of disease as described above, at 475 which time they were euthanized. 476 477
Quantification of leukemia-initiating cell frequency. Leukemia cells from spleens of three 478
Tgif1 +/+ or three Tgif1 -/mice with AML induced with the MSCV-MLL-AF9-IRES-GFP 479 retrovirus were pooled, and 1 ´ 10 6 , 1 ´ 10 5 , 1 ´ 10 4 , 1 ´ 10 3 , 100, and 50 cells were transplanted 480 into sub-lethally irradiated recipients. Animals were euthanized when they became visibly ill and 481 the development of leukemia was confirmed. LIC frequency was determined by limiting dilution 482 analysis with the ELDA (for Extreme Limiting Dilution Analysis) software package 58 . 483 484 Chemotherapy studies in AML mice. For treatment studies, 2 ´ 10 3 splenic leukemia cells from 485 Tgif1 +/+ or Tgif1 -/mice were transplanted into sub-lethally irradiated recipients by tail vein 486 injection. Two weeks after transplant, mice were treated by intraperitoneal injection with 100 487 mg/kg cytarabine once per day for five days and 3 mg/kg doxorubicin for three days. Mice were 488 monitored closely for disease development and GFP expression was evaluated weekly by FACS 489 analysis. Animals were euthanized when they appeared ill and transfer of disease was verified. conjugated with monoclonal antibodies to CD2 and CD14, respectively, and immediately 508 cryopreserved. In the case of myelomonocytic (FAB M4) or monocytic (M5) leukemias, only the 509 CD2 antibody was used. All cell populations contained at least 95% blasts and had an initial 510 viability of ≥90%. Total cellular RNA was prepared from thawed cells on silica-gel membranes 511 All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
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